Sugi Predict

Sugi Predict / Compounds / SCHEMBL1774552

SCHEMBL1774552

SCHEMBL1774552

N=C(N)NCCCCC[C]=O

nearest known ligand 0.50

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.50
▸ MEN1 O00255 2/20 0.50
▸ KMT2A Q03164 2/20 0.50
▸ CYP1A2 P05177 1/20 0.50
▸ ALOX15 P16050 1/20 0.46
▸ ALB P02768 1/20 0.36
▸ SPHK1 Q9NYA1 3/20 0.33
▸ HIF1A Q16665 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ PAOX Q6QHF9 2/20 0.32
▸ ALDH1A1 P00352 2/20 0.32
▸ TSHR P16473 1/20 0.32
▸ EPHX2 P34913 1/20 0.31
▸ EPHX1 P07099 2/20 0.30
▸ ALDH1A2 O94788 1/20 0.30
▸ ALDH2 P05091 1/20 0.30
▸ ALDH1A3 P47895 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7283594 1.00 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2ACYP1A2ALOX15
SCHEMBL5497458 1.00 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2ACYP1A2ALOX15
SCHEMBL7435955 1.00 SMN1; SMN2 (0.50) SMN1; SMN2MEN1KMT2ACYP1A2ALOX15
SCHEMBL2905696 0.98 ALOX15 (0.47) SMN1; SMN2MEN1KMT2ACYP1A2ALOX15
SCHEMBL1775038 0.91 — —
SCHEMBL1521786 0.83 DPP7 (0.49) SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1
SCHEMBL1521224 0.83 DPP7 (0.49) SMN1; SMN2MEN1KMT2ACYP1A2ALDH1A1
SCHEMBL2906945 0.82 — —
SCHEMBL3069140 0.82 SMN1; SMN2 (0.67) SMN1; SMN2MEN1KMT2ACYP1A2ALOX15
SCHEMBL1923256 0.82 SMN1; SMN2 (0.67) SMN1; SMN2MEN1KMT2ACYP1A2ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100305198-A1 CATIONIC LIPIDS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURG (GB) 2010-12-02 — — US claimed
EP-2212279-A1 CATIONIC LIPIDS The University Court Of The University of Edinburgh (GB) 2010-08-04 — — EP claimed
WO-2009050483-A1 CATIONIC LIPIDS THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) 2009-04-23 — — WO claimed
EP-0334244-A2 Bradykinin Antagonist Peptides THE PROCTER & GAMBLE COMPANY (US) 1989-09-27 — — EP claimed
US-11028386-B2 Morpholino oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2021-06-08 — — US disclosed
CN-105228999-B Process for preparing morpholino oligonucleotides 味之素株式会社 2021-03-02 — — CN disclosed
CN-106795186-B Process for preparing morpholino oligonucleotides 味之素株式会社 2021-03-02 — — CN disclosed
US-20200040331-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD AJINOMOTO CO., INC. (JP) 2020-02-06 — — US disclosed
US-10472624-B2 Morpholino oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2019-11-12 — — US disclosed
US-10415036-B2 Morpholino oligonucleotide manufacturing method AJINOMOTO CO., INC. (JP) 2019-09-17 — — US disclosed
US-20180016580-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD AJINOMOTO CO., INC. (JP) 2018-01-18 — — US disclosed
EP-2024499-B1 OLIGONUCLEOTIDE ANALOGS HAVING CATIONIC INTERSUBUNIT LINKAGES SAREPTA THERAPEUTICS INC (US) 2017-10-25 — — EP disclosed
EP-0446751-A1 Glycolic acid derivatives MERCK PATENT GmbH (DE) 1991-09-18 — — EP disclosed
EP-0418696-A2 Derivatives of aminoacids MERCK PATENT GmbH (DE) 1991-03-27 — — EP disclosed
CN-1037155-A Amino acid derivative MERCK PATENT GMBH (DE) 1989-11-15 — — CN disclosed
EP-0339483-A2 Renin inhbiting amino-acid derivatives MERCK PATENT GmbH (DE) 1989-11-02 — — EP disclosed
EP-0337334-A2 Renin-inhibiting amino acid derivatives MERCK PATENT GmbH (DE) 1989-10-18 — — EP disclosed
EP-0334244-A2 Bradykinin Antagonist Peptides THE PROCTER & GAMBLE COMPANY (US) 1989-09-27 — — EP disclosed
EP-0025897-B1 PEPTIDES AND PROCESS FOR THEIR PREPARATION HOECHST AKTIENGESELLSCHAFT (DE) 1984-03-28 — — EP disclosed
US-4420424-A New peptides and a process for their preparation HOECHST AKTIENGESELLSCHAFT (DE) 1983-12-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200040331-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD DCLRE1B, RNGTT, RTCB SMN1; SMN2 258/4885MEN1 1767/4885KMT2A 1980/4885
US-10415036-B2 Morpholino oligonucleotide manufacturing method RNGTT, RNMT, NSUN2 SMN1; SMN2 154/4885MEN1 2620/4885KMT2A 1698/4885
US-10472624-B2 Morpholino oligonucleotide manufacturing method DCLRE1B, RNGTT, RTCB SMN1; SMN2 258/4885MEN1 1767/4885KMT2A 1980/4885
US-20100305198-A1 CATIONIC LIPIDS CETP, LIPA, ABHD16A SMN1; SMN2 3534/4885MEN1 1595/4885KMT2A 2301/4885
US-11028386-B2 Morpholino oligonucleotide manufacturing method DCLRE1B, RNGTT, RTCB SMN1; SMN2 258/4885MEN1 1767/4885KMT2A 1980/4885
US-20180016580-A1 MORPHOLINO OLIGONUCLEOTIDE MANUFACTURING METHOD RNGTT, RNMT, NSUN2 SMN1; SMN2 154/4885MEN1 2620/4885KMT2A 1698/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.